Luxdegalutamide
Small molecule
Also known as ARV-766, JSB462
Evidence outlook
Mid-stage studies underway, no completed readout
Phase 2 studies are registered but none has completed a readout, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT05067140 NCT05067140 · Metastatic Castration-Resistant Prostate Cancer Registry: NCT05067140 | 1/2 | Part A: Incidence and severity of dose limiting toxicities (DLTs) during the first cycle of treatment (Up to 28 days); Part C: Incidence and severity of dose limiting toxicities (DLTs) during the first cycle of treatment (Up to 28 Days); Parts A and C: Incidence rate of Adverse Events (AEs) and Serious Adverse Events (SAEs) (From first dose through approximately 30 days after last dose); Parts A and C: Incidence of laboratory abnormalities (From first dose through approximately 30 days after last dose); Part B: Prostate-Specific Antigen 30% Response Rate (PSA30) (12 Weeks); Part B: Prostate-Specific Antigen 50% Response Rate (PSA50) (12 Weeks) 2027-05-25 | In progress: results expected 25 May 2027 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (2)
What this study did
What this study did
Phase 1/2 (2)
What this study did
What this study did
Phase 1 (1)
What this study did
Competitive landscape
Other Androgen receptor drugs
Other Androgen receptor (degrader) drugs
HRS-5041, GSK5471713. Compare all 3 Androgen receptor (degrader) drugs
3 other tracked programmes target this mechanism, 1 of them ahead of this one.
This drug's own stage for Metastatic Castration-Resistant Prostate Cancer: Phase 2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Luxdegalutamide: this drug | Phase 2 | Small molecule | Androgen receptor, Androgen receptor (degrader) | not yet graded | No reviewed efficacy summary in this indication | |
| Docetaxel (Taxotere) | Approved | Small molecule | Microtubules (tubulin) | not yet graded | No reviewed efficacy summary in this indication | |
| Olaparib | Approved | Small molecule | PARP | not yet graded | No reviewed efficacy summary in this indication | |
| Rucaparib | Approved | Small molecule | PARP (poly ADP-ribose polymerase) enzymes, PARP1/2 | Partial signal | No reviewed efficacy summary in this indication | |
| Talazoparib | Approved | Small molecule | PARP | not yet graded | No reviewed efficacy summary in this indication | |
| Elfetabart Drozuntecan | Phase 3 | Antibody–drug conjugate | B7-H3 | not yet graded | No reviewed efficacy summary in this indication | |
| Fluzoparib | Phase 3 | Small molecule | PARP (poly ADP-ribose polymerase), specifically PARP-1 | not yet graded | No reviewed efficacy summary in this indication | |
| HRS-4357 | Phase 3 | Undisclosed | PSMA | not yet graded | No reviewed efficacy summary in this indication | |
| Ifinatamab Deruxtecan | Phase 3 | Antibody–drug conjugate | B7-H3 | not yet graded | No reviewed efficacy summary in this indication | |
| Mevrometostat | Phase 3 | Small molecule | EZH2 | not yet graded | No reviewed efficacy summary in this indication | |
| Opevesostat | Phase 3 | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| Pasritamig | Phase 3 | Multispecific antibody | — | not yet graded | No reviewed efficacy summary in this indication | |
| Rezvilutamide | Phase 3(overall) | Small molecule | Androgen receptor | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Zadavotide Guraxetan | Phase 3 | Radioconjugate (actinium-225) | PSMA | not yet graded | No reviewed efficacy summary in this indication | |
| HRS-5041 | Phase 2(overall) | Small molecule | Androgen receptor (degrader) | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| ABBV-969 | Phase 1 | Undisclosed | PSMA / STEAP1 | not yet graded | No reviewed efficacy summary in this indication | |
| AKY-2519 | Phase 1 | Radiopharmaceutical | B7-H3-targeted radioligand therapy | not yet graded | No reviewed efficacy summary in this indication | |
| BPX-601 | Phase 1 | Cell therapy | PSCA | not yet graded | No reviewed efficacy summary in this indication | |
| GSK5471713 | —(overall) | Undisclosed | Androgen receptor (degrader) | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| RG6852 | —(overall) | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(5 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Luxdegalutamide to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.